0.04
+5.56%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Imugene
Its shares trade on ASX under the ticker IMU.AX. It has been listed since 2 December 1993. In the fiscal year to 30 June 2025, it reported revenue of A$4.4m and a net loss of A$69.0m. At that date it held total assets of A$83.6m and shareholders' equity of A$45.0m.
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The firm is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. The company was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The firm is also developing mimotope-based immunotherapies against validated and oncology targets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Dec 1993
- Website
- imugene.com ↗
Leadership
Pay as last reported
- Mr. Paul HopperExecutive Chairman of the Board, since 2012A$322,687
- Ms. Leslie ChongChief Executive Officer, Managing Director, Executive Director, since 2015A$1.4m
- Mr. Darren KeamyChief Financial Officer, Company Secretary
- Dr. Bradley GloverChief Operating OfficerA$808,065
- Dr. Monil ShahChief Business OfficerA$798,535
- Dr. Paul WoodardChief Medical OfficerA$884,198
- Ms. Kimberlee DrapkinNon-Executive Independent DirectorA$76,562
- Dr. Jakob DupontNon-Executive Independent DirectorA$76,153
- Dr. Lesley RussellNon-Executive Independent DirectorA$76,153
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 42
- Social
- 62
- Governance
- 21
- Women in the workforce
- 59%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Imugene Ltd has a strong portfolio of innovative biotechnology products, providing them with a competitive advantage in the market. Their products have shown promising results in the treatment of various diseases, positioning the company as a leader in the industry.
Weaknesses
- One of the weaknesses of Imugene Ltd is its heavy reliance on external funding for research and development. This raises concerns about the company's financial stability and ability to sustain long-term growth. Additionally, Imugene Ltd may lack the resources and infrastructure compared to larger competitors.
Opportunities
- There are several opportunities for Imugene Ltd to capitalize on. The increasing demand for effective biotechnology solutions presents a significant market potential for the company. Moreover, strategic partnerships and collaborations with established pharmaceutical companies can provide access to additional resources and expand Imugene Ltd's market presence.
Threats
- Imugene Ltd faces several threats that could impact its operations. Regulatory hurdles and compliance requirements in the biotechnology industry present challenges that may delay product approvals and market entry. Furthermore, intense competition from other biotechnology companies with similar products and technologies can erode Imugene Ltd's market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.